Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.49 |
| ▸ | WNT3A | P56704 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661011 | 0.85 | PDE4B (0.62) | PDE4BMAPTTSHRALDH1A1CTNNB1 | |
| SCHEMBL20116207 | 0.84 | PDE4B (0.61) | PDE4BMAPTTSHRALDH1A1CTNNB1 | |
| SCHEMBL661271 | 0.80 | ALDH1A1 (0.56) | PDE4BMAPTTSHRALDH1A1CYP1A2 | |
| SCHEMBL4277719 | 0.80 | MAPK1 (0.59) | PDE4BMAPTTSHRALDH1A1CYP1A2 | |
| SCHEMBL3924278 | 0.80 | CA12 (0.73) | PDE4BTSHRALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL25139577 | 0.79 | MEN1 (0.62) | PDE4BMAPTTSHRALDH1A1CTNNB1 | |
| SCHEMBL6822927 | 0.78 | L3MBTL1 (0.54) | ALDH1A1MAPK1MEN1KMT2ATUBB4A | |
| SCHEMBL7353148 | 0.78 | PDE4B (0.54) | PDE4BMAPTTSHRALDH1A1CYP1A2 | |
| SCHEMBL28663604 | 0.78 | MAPT (0.66) | PDE4BMAPTTSHRALDH1A1CYP1A2 | |
| SCHEMBL1421889 | 0.76 | MAPT (0.73) | PDE4BMAPTTSHRALDH1A1CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091240-B2 | Tubulin binding ligands and corresponding prodrug constructs | OXIGENE, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040044059-A1 | Destroying tumor cell vasculation; antitumor agents; anticancer agents | MATEON THERAPEUTICS, INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044059-A1 | Destroying tumor cell vasculation; antitumor agents; anticancer agents | FLT4, TUBB3, FLT1 | PDE4B 1447/4885MAPT 208/4885TSHR 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.